Speciality
Spotlight

 




 


Oncology


 

 





Interleukin

    

  • Rosenberg SA, Yang JC, White DE, et al [NIH, Bethesda, Md]

    Durability of Complete Responses in Patients With Metastatic Cancer Treated with High-Dose interleukin – 2: identification of the Antigens Mediating Response

    Ann Surg 228: 307-319, 1998

         

    This article analyzes the characteristics of 9.3% patients with metastatic renal cell carcinoma and the 6.6% of patients with metastatic melanoma who were treated with high dose lL-2 and sustained a complete clinical response. 

      

    Three parameters correlated with a complete response –

    1. Absence of prior immunotherapy.

    2. The total amount of lL-2 administered.

    3. The magnitude of lymphocyte rebound immediately after completion of therapy.

      

    The rigid rebound of lymphocytes after completion of lL-2 therapy generally implies that the lymphocytes had become marginated along the endothelial surface, and biopsy findings suggest that this may be most remarkable in the tumor. If this is the case, identification of molecules responsible for adherence of lymphocytes to the endothelium and the possible synergism of this form of immunotherapy with antiangiogenesis approaches is tantalizing.

      


 

 



 

 

Speciality Spotlight

 

 

Interleukin
    

  • Rosenberg SA, Yang JC, White DE, et al [NIH, Bethesda, Md]
    Durability of Complete Responses in Patients With Metastatic Cancer Treated with High-Dose interleukin – 2: identification of the Antigens Mediating Response
    Ann Surg 228: 307-319, 1998
         
    This article analyzes the characteristics of 9.3% patients with metastatic renal cell carcinoma and the 6.6% of patients with metastatic melanoma who were treated with high dose lL-2 and sustained a complete clinical response. 
      
    Three parameters correlated with a complete response –
    1. Absence of prior immunotherapy.
    2. The total amount of lL-2 administered.
    3. The magnitude of lymphocyte rebound immediately after completion of therapy.
      
    The rigid rebound of lymphocytes after completion of lL-2 therapy generally implies that the lymphocytes had become marginated along the endothelial surface, and biopsy findings suggest that this may be most remarkable in the tumor. If this is the case, identification of molecules responsible for adherence of lymphocytes to the endothelium and the possible synergism of this form of immunotherapy with antiangiogenesis approaches is tantalizing.
      

 

 

 

By |2022-07-20T16:42:23+00:00July 20, 2022|Uncategorized|Comments Off on Interleukin

About the Author: